Skip to main content

Author Guidelines

Please adhere to the following guidelines. If you have any questions please contact

MISSON STATEMENT—The Journal of Hematology Oncology Pharmacy (JHOP) is an independent, peer-reviewed journal founded in 2011 to provide hematology and oncology pharmacists and other healthcare professionals in these fields with high-quality information relevant to hematologic and oncologic conditions to help them optimize drug therapy for patients.

The editors invite readers to submit articles on a variety of points of view and approaches relevant to the practice of US hematology oncology pharmacists to meet the mission of the journal.

GENERAL INFORMATIONManuscripts submitted to JHOP must be original and must not have been published previously, either in print or in electronic form. Manuscripts cannot be submitted elsewhere while under consideration by JHOP. Manuscripts accepted for publication in JHOP cannot be published in another publication without written permission from the publisher. The corresponding author must sign a Copyright Transfer Form (with consent from and on behalf of all the authors), and all authors must complete an Author Disclosure Form.

JHOP follows the recommendations of the International Committee of Medical Journal Editor’s (ICMJE)1 uniform requirements and the Principles of Transparency and Best Practice in Scholarly Publishing,2 a joint statement released by the Committee on Publication Ethics (COPE), the Directory of Open Access Journals (DOAJ), the World Association of Medical Editors (WAME), and the Open Access Scholarly Publishing Association (OASPA) for manuscript preparation, review, editing, and publication. The full ICMJE recommendations can be accessed at, and the complete joint statement by COPE, DOAJ, WAME, and OASPA is located at

Articles are divided into 5 main categories: (1) Original Research provides an outlet for translational and practice-based research and adds something to the current literature; (2) Review Articles that focus on drug and disease state, as well as on basic science regarding the complex molecular biology of cancer with an oncology pharmacy focus; (3) Case Report, which describes ≥1 real-world unique cases and includes a review of the relevant literature, the approach to diagnosis and treatment, and explains how this report adds to the literature; (4) Practical Issues in Pharmacy Management could be either an Original Research or a Review Article that is focused on real-world issues involving logistics, economics, and other practice-related topics; and (5) Symptom Management Overview, focusing on a specific symptom, its etiology, and management. In addition, JHOP invites readers to submit Letters to the Editor and Perspectives. Click here for guidance on those categories .

DISCLOSURE STATEMENTS—All authors must disclose any relationship that could be viewed as a potential conflict of interest, based on ICMJE guidelines,1 including any financial interests, direct or indirect, and any affiliations or involvement (competitive or amiable) with organizations that have a financial interest in the subject matter or materials discussed in the manuscript. Each author must sign the Financial Disclosure Form in accordance with the ICMJE guidelines.1

JHOP discloses all information regarding employment, consultancies, stock ownership, honoraria, grants, or other financial sources with potential conflict of interest in relation to a manuscript, or if authors discuss any products or services with such commercial interest. Any information regarding funding, grants, or other financial compensation must be listed on the title page of the manuscript. All published articles will include an Author Disclosure Statement listing any relationships with real or potential conflict of interest for all authors and for the manuscript/research.

Any funding source must be disclosed on the title page of the manuscript. The funding company/entity cannot intervene in the editorial content and process.

STATEMENT ON ARTIFICIAL INTELLIGENCE (AI)—It is the responsibility of the authors to disclose both during the submission process and within the submitted work in the appropriate section if applicable, whether they used artificial intelligence–assisted technologies in the preparation of the submitted article. For example, if artificial intelligence was used for data collection, analysis, or figure generation, authors should describe this use in the methods section of their article.

PERMISSIONS—Authors must secure written permission to reuse or adapt any graphic elements (table, figure) from a previously published (online or in print) article or from any other source. Provide the letter of permission when submitting the manuscript, or indicate that permission will be provided, and cite the original source with the graphic element in the manuscript. Authors are responsible for acknowledging all information that has been published previously.

MANUSCRIPT FORMAT—Manuscripts that do not adhere to the format described in this document will be returned to the author for revision.

NOTE: Identifying information (eg, author names, affiliations) must NOT be included anywhere in the manuscript, in order to comply with JHOP's double-anonymized peer-review process. These details (including author names, titles, affiliations, degrees, and corresponding author contact information) will be collected during the submission process.

Title: Include a proper title at the beginning of the article.

Funding Source(s): All funding sources for the study/article must be listed on page 1 of the manuscript. If no funding was received in relation to the study/article, please state that on page 1.

Abstract: Articles must include an abstract (200-350 words) that describes the main objective of the article, why this article is important to hematology oncology pharmacists, and what it adds to the current literature.

Original Research/Practical Issues in Pharmacy Management: The abstract must include: Background, Objective, Methods, Results, and Conclusion.

Review Article: The abstract must include: Background, Objective, Discussion, Conclusion, and why the article is important to hematology oncology pharmacists.

Case Report: The abstract should be brief and include: Background, Discussion, Conclusion. Body should include Background/Introduction (the condition), Patient Cases, Discussion (cases vs current literature), Conclusion (what is new here). The case report must be unique and add something new to the literature. May include ≥1 cases. Minimum 1 Table or Figure per each case.

Symptom Management Overview: Describe the symptom(s) of the condition, the etiology, and treatment options. Minimum 1 Table, maximum 3.

Letters to the Editor: Readers are invited to submit Letters to the Editor in response to an article published in the Journal (or a general topic). All accepted Letters are published in the print journal and/or online on the Journal's website. Authors are asked to respond to such comments. Please send all correspondence regarding published articles to Click here for more information.

Perspectives: Readers may submit original perspectives pieces on topics relevant to the hematology/oncology pharmacy community. For more information, click here.

Text: The entire text must be provided as a double-spaced Word file and all pages numbered consecutively. Cite any graphic elements (Tables, Figures, Appendix) consecutively in the text, but place actual tables/figures/appendix at the end of the article, after the references. Limit the length of the text to approximately 3500 words (excluding references, tables, and figures).

Conclusion: The conclusion should add something new to the article, a point of view or comments related to the rationale for the article and what the article adds to the literature, not a summary of the article.

Tables and figures: Minimum 1, maximum 6 tables and figures combined. Exceptions: Case Report: Minimum 1 Table/Figure. Symptom Management Overview: Minimum 1 Table, Maximum 3. Additional items can be posted online as an Appendix. Cite all figures, tables, algorithms, and other graphics in the text, but place the graphic elements at the end of the article, after the references.

Figures and other images (excluding tables) must also be provided as individual graphic files, saved at high resolution (300 dpi), as an image file or pdf file. Attach an individual file for each image. Images not saved appropriately will delay the peer-review process significantly. For help with images, please contact

References: Use the most up-to-date, post-2010 (except for “classic” sources), primary sources only (namely, the original study or source, not a secondary article that is citing the primary study). References must be cited consecutively in the text (as superscript numbers), then place each complete reference at the end of the article under heading “References.” Please do not use automatic numbering or footnote/endnote features. Try to limit the number of references to 45.

Use citation format according to the AMA Manual of Style.3


  1. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676-680.
  2. McGrath JJ, Murray RM. Risk factors for schizophrenia: from conception to birth. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Blackwell Press; 2003.
  3. Waters R, Pettypiece S. Drug sales in the US grow at slower pace as generic use surges. Bloomberg News. March 12, 2008. Accessed March 13, 2008.

PEER REVIEW—All articles undergo an initial internal review by journal staff and section editors for topic appropriateness and manuscript format. Manuscripts that do not follow the guidelines in this document will be returned to the author for revisions.

All manuscripts are subject to a strict, double-anonymized peer review (by 2-3 reviewers), and acceptance is determined by the section editor based on that review. Reviewers look for accuracy of the information and data presented, as well as relevance to the objectives of JHOP.

All authors’ identifying information is removed from the article for the purpose of the peer review, but any study funding information is provided to reviewers. The peer-review process is conducted with full confidentiality: journal staff, section editors, and peer reviewers are instructed to not share any information regarding the submission of an article, or any aspect of the article, before publication. In addition, reviewers are instructed to delete electronic copies of the manuscript and destroy any paper copies, once they have submitted a review.

Authors are notified as soon as possible regarding the initial decision of acceptance or rejection of the article. The majority of articles that are accepted for publication, however, will require revisions before acceptance.

Authors may appeal an editorial decision. Together with the relevant section editor involved in the original review, the Journal’s co-editors-in-chief will carefully reassess the submitted article plus any revisions that the authors have instituted in response to an appealed rejection.

EDITING—Once accepted, all articles are edited for substance and to conform to house style, following, in part, the AMA Manual of Style, 11th ed.3 The edited manuscript is sent to the corresponding author for a final review and for any editorial queries. Time from submission to publication varies greatly and is generally 8 to 14 months, but could be longer, depending on the peer-review and revision processes.

AUTHORSHIP/COPYRIGHT—Authors should only include those who have made a direct contribution to the content of the article, in accordance with the authorship criteria provided by the ICMJE.1 Credit for authorship is based on a substantial contribution to (1) the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work; (2) drafting the work or reviewing it critically for important intellectual content; (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.1 These 4 criteria must all be met. Those who have contributed to the article but do not meet these authorship criteria should be included in an acknowledgment (gathered during submission but not listed directly in the manuscript file, to comply with JHOP's double-anonymized peer-review policy).

When prompted during the submission process, please provide authors’ highest academic degree and professional affiliations, including job title and location. Also provide the name, address, telephone number, and email of the corresponding author. The corresponding author is responsible for securing signatures for all forms from all authors.

The corresponding author is required to sign a Copyright Transfer Form (with the consent of all coauthors to sign on their behalf), assigning all copyrights for the manuscript to Amplity Health, publisher of JHOP.

For an article to be considered for publication, the authors must adhere to the manuscript format described here.

HOW TO SUBMIT MANUSCRIPTS—Submit articles online at Articles that do not follow the guidelines described in this document will be returned to the author for revisions.

Submit the entire manuscript and accompanying documents via JHOP's online submission portal, Editorial Manager. For more information, click the button below.


REPRINTS—Reprints may be ordered for a nominal fee by contacting

  1. International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. Updated January 2024. Accessed May 6, 2024.
  2. Committee on Publication Ethics; Directory of Open Access Journals; Open Access Scholarly Publishing Association; World Association of Medical Editors. Principles of Transparency and Best Practice in Scholarly Publishing. Version 4.0. September 2022. Accessed May 6, 2024.
  3. AMA Manual of Style, 11th ed. Oxford University Press; 2020.